Recent chatter on X about Precigen, Inc. (PGEN) has exploded following the FDA's approval of Papzimeos, a groundbreaking gene therapy for recurrent respiratory papillomatosis. Many users are buzzing with excitement over the stock's dramatic pre-market surge of over 50%, viewing it as a validation of the company’s innovative platform. The news has sparked intense interest, with some highlighting raised price targets by analysts as a sign of strong future potential.
Discussions on X also reflect a sense of optimism about Precigen’s broader pipeline, with several pointing to this approval as a stepping stone for other therapies in development. While the mood is largely celebratory, a few voices caution that such rapid gains could lead to volatility in the near term. This pivotal moment has clearly positioned PGEN as a focal point for biotech investors on the platform.
Note: This discussion summary was generated from an AI condensation of post data.
Precigen, Inc. Hedge Fund Activity
We have seen 69 institutional investors add shares of Precigen, Inc. stock to their portfolio, and 55 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PARKMAN HEALTHCARE PARTNERS LLC added 3,191,343 shares (+inf%) to their portfolio in Q1 2025, for an estimated $4,755,101
- SCHONFELD STRATEGIC ADVISORS LLC added 2,794,249 shares (+inf%) to their portfolio in Q1 2025, for an estimated $4,163,431
- PATIENT CAPITAL MANAGEMENT, LLC removed 1,103,560 shares (-6.4%) from their portfolio in Q2 2025, for an estimated $1,567,055
- MORGAN STANLEY added 1,007,864 shares (+97.6%) to their portfolio in Q2 2025, for an estimated $1,431,166
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 975,244 shares (+593.0%) to their portfolio in Q2 2025, for an estimated $1,384,846
- RENAISSANCE TECHNOLOGIES LLC removed 505,400 shares (-63.7%) from their portfolio in Q2 2025, for an estimated $717,668
- D. E. SHAW & CO., INC. removed 424,900 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $633,101
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Precigen, Inc. Analyst Ratings
Wall Street analysts have issued reports on $PGEN in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 08/15/2025
- JMP Securities issued a "Market Outperform" rating on 06/12/2025
- Cantor Fitzgerald issued a "Overweight" rating on 05/15/2025
- Citizens Capital Markets issued a "Market Outperform" rating on 03/20/2025
To track analyst ratings and price targets for Precigen, Inc., check out Quiver Quantitative's $PGEN forecast page.
Precigen, Inc. Price Targets
Multiple analysts have issued price targets for $PGEN recently. We have seen 3 analysts offer price targets for $PGEN in the last 6 months, with a median target of $6.0.
Here are some recent targets:
- Swayampakula Ramakanth from HC Wainwright & Co. set a target price of $8.5 on 08/15/2025
- Jason Butler from JMP Securities set a target price of $6.0 on 06/12/2025
- Jason Butler from Citizens Capital Markets set a target price of $6.0 on 03/20/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
